Etanercept | Infliximab | Adalimumab | Rituximab | Tocilizumab | Certolizumab | |
Number of patients | 8630 | 4908 | 7818 | 5101 | 2174 | 1446 |
Follow-up time in years | 15 314 | 8829 | 13 071 | 5910 | 1963 | 1685 |
Infections: single failure | 852 | 472 | 709 | 372 | 137 | 64 |
Incidence per 100 patient years (95% CI)* | 5.56 (5.20 to 5.95) | 5.35 (4.89 to 5.85) | 5.42 (5.04 to 5.84) | 6.29 (5.69 to 6.97) | 6.98 (5.90 to 8.25) | 3.80 (2.97 to 4.85) |
Unadjusted HR (95% CI) | Ref | 0.94 (0.84 to 1.06) | 0.97 (0.88 to 1.07) | 1.15 (1.01 to 1.30) | 1.22 (1.02 to 1.47) | 0.65 (0.51 to 0.84) |
Adjusted HR (95% CI) | Ref | 0.89 (0.79 to 1.00) | 1.00 (0.90 to 1.10) | 0.91 (0.80 to 1.03) | 1.21 (1.01 to 1.46) | 0.75 (0.58 to 0.97) |
Covariates included in the adjusted model were age, gender, Disease Activity Score 28-erythrocyte sedimentation rate, Health Assessment Questionnaire, disease duration, smoking, seropositivity, polypharmacy and baseline steroid usage.
*Unadjusted incidence.